CN109331049B - New use of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil - Google Patents
New use of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil Download PDFInfo
- Publication number
- CN109331049B CN109331049B CN201811145935.3A CN201811145935A CN109331049B CN 109331049 B CN109331049 B CN 109331049B CN 201811145935 A CN201811145935 A CN 201811145935A CN 109331049 B CN109331049 B CN 109331049B
- Authority
- CN
- China
- Prior art keywords
- ganoderma lucidum
- lucidum spore
- spore oil
- oil
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 112
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 112
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 206010028594 Myocardial fibrosis Diseases 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 20
- 208000030134 Aortic valvular disease Diseases 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 17
- 229930195729 fatty acid Natural products 0.000 claims description 17
- 239000000194 fatty acid Substances 0.000 claims description 17
- 150000004665 fatty acids Chemical class 0.000 claims description 17
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 150000003648 triterpenes Chemical class 0.000 claims description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 8
- 239000005642 Oleic acid Substances 0.000 claims description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
- 235000021313 oleic acid Nutrition 0.000 claims description 8
- 238000009210 therapy by ultrasound Methods 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 5
- 102000035092 Neutral proteases Human genes 0.000 claims description 5
- 108091005507 Neutral proteases Proteins 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000006386 neutralization reaction Methods 0.000 claims description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 235000013376 functional food Nutrition 0.000 abstract description 7
- 239000003921 oil Substances 0.000 description 70
- 235000019198 oils Nutrition 0.000 description 70
- 230000002265 prevention Effects 0.000 description 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 8
- 229940118019 malondialdehyde Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 241001489091 Ganoderma sinense Species 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/02—Pretreatment
- C11B1/025—Pretreatment by enzymes or microorganisms, living or dead
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/02—Pretreatment
- C11B1/04—Pretreatment of vegetable raw material
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
- C11B1/104—Production of fats or fatty oils from raw materials by extracting using super critical gases or vapours
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Hospice & Palliative Care (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of ganoderma lucidum spore oil and/or a pharmaceutical composition containing ganoderma lucidum spore oil in preparing functional food and medicines with the effect of preventing myocardial fibrosis caused by aortic valvular disease, and the invention discloses new application of ganoderma lucidum spore oil and/or a pharmaceutical composition containing ganoderma lucidum spore oil in preventing myocardial fibrosis caused by aortic valvular disease for the first time, and provides a new method for preventing myocardial fibrosis caused by aortic valvular disease.
Description
Technical Field
The invention belongs to the technical field of ganoderma lucidum spore oil, and particularly relates to application of ganoderma lucidum spore oil and/or a pharmaceutical composition containing ganoderma lucidum spore oil in preparation of functional food and medicines with the effect of preventing myocardial fibrosis caused by aortic valvular disease.
Background
Myocardial fibrosis is induced by diseases such as hypertension, atherosclerosis, valvular disease, hyperlipidemia, atrial fibrillation, and the like, and the disease mechanism involves myofibroblast activation, collagen concentration increase, extracellular matrix excessive deposition, glycolipid metabolism abnormality, and the like. Myocardial fibrosis is ultimately classified as cardiac remodeling, systolic-diastolic dysfunction and heart failure. Early prevention is of great significance as a progressive disease, but currently there is no reliable method for preventing myocardial fibrosis. In the innovative research and development of myocardial fibrosis prevention drugs, based on the fact that the inducers are various and the mechanism is complex, the mechanism of the drug action needs to be accurately evaluated by aiming at the specific inducers. The medicine of the invention aims at preventing myocardial fibrosis caused by aortic valvular disease, and proves the prevention effect of the medicine from multiple mechanisms.
After aortic valve pathology occurs, the heart becomes overloaded with excess blood retention and eventually develops myocardial fibrosis. Aortic valvular lesions are the third most common cardiovascular disease next to hypertension and coronary heart disease. The incidence rate of aortic valvular disease counted in the United states in the elderly is as high as 2.5%, and the incidence rate of aortic valvular disease in China is higher than that in the United states according to the conjecture of parts of China. As China enters an aging society, the incidence of various cardiovascular diseases is expected to be continuously increased, and the cardiovascular diseases become a great public health problem in China, the innovative development of early prevention strategies has great significance.
The Ganoderma effective components can be obtained by water extraction, alcohol extraction, supercritical carbon dioxide extraction, etc., and comprise Ganoderma polysaccharides, Ganoderma triterpene/sterol, and fatty acid. Research shows that the ganoderma lucidum extract can treat myocardial fibrosis, but the application of the ganoderma lucidum extract (particularly oily components) in preventing myocardial fibrosis, particularly myocardial fibrosis caused by aortic valvular disease is not available.
The ganoderma lucidum variety recorded in the pharmacopoeia is ganoderma lucidum and ganoderma sinense at present, and in the difference analysis of the two varieties, research shows that ganoderma sinense has more advantages in reducing triglyceride than ganoderma sinense, and because the prevalence rate of hyperlipidemia in China is continuously increased, the ganoderma sinense has more clinical application value.
Disclosure of Invention
The invention aims to provide application of ganoderma lucidum spore oil and/or a pharmaceutical composition containing ganoderma lucidum spore oil in preparation of functional food and medicines with the effect of preventing myocardial fibrosis caused by aortic valvular disease.
The above object of the present invention is achieved by the following technical solutions: application of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil in preparing functional food and medicine for preventing myocardial fibrosis caused by aortic valvular disease is provided.
As a preferred technical scheme, the ganoderma lucidum spore oil is prepared by the following method:
(1) selecting Ganoderma lucidum spore powder, performing ultrasonic treatment, freezing the Ganoderma lucidum spore powder with liquid nitrogen for multiple times, rewarming, adding neutral protease for enzymolysis, performing enzyme deactivation, neutralization, filtration and drying treatment after enzymolysis to obtain pretreated Ganoderma lucidum spore powder;
(2) and performing supercritical extraction on the pretreated ganoderma lucidum spore powder by adopting carbon dioxide to obtain ganoderma lucidum spore oil.
In the method for preparing ganoderma lucidum spore oil:
preferably, in the step (1), the ganoderma lucidum spore powder after ultrasonic treatment is frozen for 2-4 times by liquid nitrogen, and then rewarming is carried out at 28-32 ℃.
Preferably, in the step (1), the ganoderma lucidum spore powder after ultrasonic treatment is frozen for 3 times by adopting liquid nitrogen, and then rewarming is carried out at 30 ℃.
Preferably, the addition amount of the neutral protease in the step (1) is 1800-2200U/g, the temperature during enzymolysis is 48-52 ℃, the enzymolysis time is 50-70 min, and the pH value is 7.2-7.6.
Preferably, the addition amount of the neutral protease in the step (1) is 2000U/g, the temperature during enzymolysis is 50 ℃, the enzymolysis time is 60min, and the pH value is 7.4.
And (2) adopting potassium hydroxide for neutralization in the step (1), wherein the drying temperature is 45-55 ℃, and the drying time is 8-12 h.
Preferably, potassium hydroxide is adopted for neutralization in the step (1), the drying temperature is 50 ℃, and the drying time is 10 hours.
Preferably, when the supercritical extraction is carried out by adopting carbon dioxide in the step (2), the extraction pressure is 14-16 Mpa, the temperature is 38-42 ℃, and the time is 1.5-2.5 h; the separation pressure is 5-7 Mpa, and the temperature is 28-32 ℃.
Preferably, when the supercritical extraction is carried out by adopting carbon dioxide in the step (2), the extraction pressure is 15Mpa, the temperature is 40 ℃, and the time is 2 hours; the separation pressure was 6MPa and the temperature was 30 ℃.
Preferably, the supercritical extraction is carried out by adopting carbon dioxide to obtain an extract containing the ganoderma lucidum spore oil, wherein the mass percentage of the ganoderma lucidum spore oil in the extract is 24-30%.
The ganoderma lucidum spore oil obtained by the invention comprises ganoderma lucidum total triterpenes and fatty acids, wherein the ganoderma lucidum total triterpenes account for 17-19% of the total mass of the ganoderma lucidum spore oil, the fatty acids account for 73-75% of the total mass of the ganoderma lucidum spore oil, and the fatty acids comprise oleic acid, palmitic acid and linoleic acid, wherein the oleic acid, the palmitic acid and the linoleic acid account for 60-63%, 15-16% and 12-14% of the total mass of the fatty acids.
More preferably, in the step (2), the ganoderma lucidum spore oil accounts for 27% of the total mass of the extract, the ganoderma lucidum spore oil comprises ganoderma lucidum total triterpenes and fatty acids, the ganoderma lucidum total triterpenes account for 18.7% of the total mass of the ganoderma lucidum spore oil, the fatty acids account for 73-75% of the total mass of the ganoderma lucidum spore oil, and the fatty acids comprise oleic acid, palmitic acid and linoleic acid, wherein the oleic acid, the palmitic acid and the linoleic acid account for 61.5%, 15.6% and 13.3% of the total mass of the fatty acids respectively.
The pharmaceutical composition containing ganoderma lucidum spore oil is a pharmaceutical composition with the effect of preventing myocardial fibrosis caused by aortic valvular disease, and preferably, the pharmaceutical composition containing ganoderma lucidum spore oil comprises ganoderma lucidum spore oil and auxiliary materials. Preferably, the auxiliary materials are conventional auxiliary materials adopted in the field of pharmacy.
Preferably, the dosage form of the pharmaceutical composition containing ganoderma lucidum spore oil is emulsion or soft capsule.
The invention has the following advantages: the invention discloses the new application of ganoderma lucidum spore oil and/or a pharmaceutical composition containing ganoderma lucidum spore oil in the aspect of preventing myocardial fibrosis caused by aortic valvular disease for the first time, and provides a new method for preventing myocardial fibrosis caused by aortic valvular disease.
Drawings
FIG. 1 is a time chart of administration of the anti-fibrotic drug and Ganoderma lucidum spore oil in example 2;
FIG. 2 shows the Masson trichrome staining of the left ventricle cross section of the mouse in example 2;
FIG. 3 shows the results of the ultrasonic testing of the mice of each group in example 2;
FIG. 4 shows that the prevention of Ganoderma lucidum spore oil in example 2 significantly reduced the extracellular matrix content in serum;
FIG. 5 shows the results of detecting superoxide dismutase SOD, MDA and GSH in heart tissue of each group of mice in example 2.
Detailed Description
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and description, and is in no way intended to limit the invention.
Example 1
The method for extracting ganoderma lucidum spore oil provided by the embodiment comprises the following steps:
(1) taking 1000g of commercial ganoderma lucidum spore powder, carrying out ultrasonic treatment, mixing the ganoderma lucidum spore powder subjected to ultrasonic treatment, freezing for 3 times by adopting liquid nitrogen, rewarming at 30 ℃, then carrying out enzymolysis by using neutral protease at 50 ℃ and pH 7.4 for 1 hour, and neutralizing by using potassium hydroxide after carrying out acid inactivated enzyme after enzymolysis.
(2) Filtering spore powder, drying at 50 ℃ for 10 hours, placing the spore powder in an extraction kettle, and performing supercritical extraction by using carbon dioxide, wherein the set conditions are as follows: extracting under 15MPa at 40 deg.c for 2 hr; ② the separation pressure is 6Mpa, the temperature is 30 ℃; (iii) CO2The speed was 20L/h.
The ganoderma lucidum spore oil is determined by a GC-MS method, the mass percentage of the ganoderma lucidum spore oil to the total mass of the extract is 27%, the ganoderma lucidum spore oil comprises total triterpenes and fatty acids, the total triterpenes of the ganoderma lucidum accounts for 18.7% of the total mass of the ganoderma lucidum spore oil, the fatty acids account for 74% of the total mass of the ganoderma lucidum spore oil, and the fatty acids comprise oleic acid, palmitic acid and linoleic acid, wherein the oleic acid, the palmitic acid and the linoleic acid account for 61.5%, 15.6% and 13.3% of the total mass of the fatty acids respectively.
Example 2
The efficacy of ganoderma lucidum spore oil in preventing myocardial fibrosis caused by aortic valvular disease is verified by experiments below.
1. Laboratory animal
After weaning, 48C 57 mice with the age of 4 weeks were bred in the SPF facility of the Guangdong laboratory animal monitoring department, the temperature and humidity in the facility were constant, the animals were irradiated with light for 12 hours every day, and the animals were automatically fed with drinking water. The experiments were performed in AAALAC certified facilities.
2. Experimental Material
(1) Ganoderma lucidum spore oil: prepared as in example 1 and stored at 4 ℃ until use.
(2) Superoxide dismutase (SOD), Malondialdehyde (MDA) and Glutathione (GSH) detection kit: purchased from Nanjing to build a bioengineering institute;
(3) HA and LN detection kit: purchased from Shanghai research medical Biotechnology, Inc.;
(4) other conventional consumables: isoflurane, 4-0 suture needle with thread, 2-0 suture needle with thread, hematoxylin, ethanol, xylene, etc.
3. Experimental methods
(1) Preparation of mouse model of myocardial fibrosis caused by aortic valvular disease
The mouse is anesthetized by 1.5% -2% isoflurane intubation, the valve position is determined by ultrasonic induction after the chest is opened, a probe is used for carrying out partial valve injury, meanwhile, stenosis is carried out at the root part of the aorta, and the successful supermode is determined by judging that the outflow of the blood flow at the rear section of the aortic stenosis part is reduced by 20% -30%. The model is used for simulating the heart blood volume and pressure overload state after aortic valvulopathy, and is characterized by myocardial fibrosis, cardiac function damage, cardiac remodeling and heart failure. The placebo group performed open-chest hand speeds without damaging valves and stenosed vessels.
(2) Grouping animals
The 72C 57 mice were randomly divided into 6 groups of 12 mice each, which were: blank control group, model control group, anti-myocardial fibrosis drug group, Ganoderma lucidum spore oil low dose prevention group (10 mg/kg/day), Ganoderma lucidum spore oil medium dose prevention group (20 mg/kg/day), and Ganoderma lucidum spore oil high dose prevention group (50 mg/kg/day). Corn oil was gavaged during the non-dosing period in the blank control group or other experimental groups, and the detailed dosing is shown in table 1. The 42 days of the first experiment were "preventive" treatments given to ganoderma lucidum spore oil, after which modeling was initiated. The second 42 days after modeling, ultrasonic testing of cardiac structural function, and after anesthesia, blood sampling and euthanasia were performed on mice, extracellular cell matrix examination was performed on serum, and histological examination was performed on heart.
TABLE 1 Ganoderma lucidum spore oil pharmacodynamic test group (n ═ 12)
The schedule of administration of the anti-fibrotic drugs and ganoderma lucidum spore oil is shown in figure 1.
(3) Morphological examination
The heart after 42 days of treatment is perfused with 4% paraformaldehyde, fixed overnight, and then subjected to conventional dehydration and paraffin embedding. Sections were 3 μm and stained using Masson trichrome staining.
Dyeing step: dissolving wax in a slicing oven, dehydrating, washing, staining with hematoxylin for 5min, and bluing for 30 min; staining with Masson ponceau for 5min, staining with glacial acetic acid, and differentiating with phosphomolybdic acid; dehydrating and transparent by using gradient ethanol and dimethylbenzene, and sealing after air drying.
And thirdly, calculating the visual field of the section with the area of the myocardial fibers between the myocardial cells being 40 times, and randomly taking the average of five visual fields. During calculation, blood vessels and cracks caused by slicing are not calculated.
The slicing results are shown in FIG. 2, and the observation in FIG. 2 shows that:
(a) the myocardial cell arrangement disorder, muscle fiber breakage and dissolution of the model control group can be seen; and the myocardial fibrosis resistant drug group, the ganoderma lucidum spore oil low-dose prevention group, the ganoderma lucidum spore oil medium-dose prevention group and the ganoderma lucidum spore oil high-dose prevention group are uniform in arrangement of myocardial cells, uniform in cytoplasmic staining, uniform in collagen tissue distribution and consistent in performance with a blank control group.
(b) The areas occupied by the myocardial fibers of the blank control group, the model control group, the myocardial fibrosis resistant drug group, the ganoderma lucidum spore oil low-dose prevention group, the ganoderma lucidum spore oil medium-dose prevention group and the ganoderma lucidum spore oil high-dose prevention group are respectively 8.2 +/-0.2%, 65.6 +/-6%, 11.8 +/-0.4%, 25.9 +/-0.3%, 24.2 +/-0.6% and 17.1 +/-0.5%, which indicates that the ganoderma lucidum spore oil prevention effect is obvious, and the ganoderma lucidum spore oil low-dose prevention group, the ganoderma lucidum spore oil medium-dose prevention group and the ganoderma lucidum spore oil high-dose prevention group respectively reduce the myocardial fiber areas by 60.5%, 63.1% and 73.9%. The above results indicate that ganoderma lucidum spore oil can prevent myocardial fibrosis caused by valvular disease.
(4) Cardiac functional ultrasound detection
Cardiac ultrasound functional testing uses a small animal high frequency ultra high resolution imaging system Vevo 2100. During detection, 2% isoflurane is used for inducing anesthesia on a mouse, the mouse is fixed on an ultrasonic operating table, the temperature is kept at 37.6 ℃, the heart rate of the mouse is maintained at 450-480 bpm in the imaging process, the short axis view beside the sternum is taken, and the heart function of the mouse is calculated through M-type measurement.
The results show (see table 2):
(a) compared with the blank control group, the model control group has the advantages of increased left heart inner diameter, increased ventricular volume, reduced stroke volume and obviously reduced contractility.
(b) Compared with a model control group, the myocardial fibrosis resistant drug rents, the ganoderma lucidum spore oil low-dose prevention group, the ganoderma lucidum spore oil medium-dose prevention group and the ganoderma lucidum spore oil high-dose prevention group have obvious improvement on the left ventricle inner diameter, the ejection fraction, the short axis shortening rate and the cardiac output. For example, on the most intuitive index ejection fraction of the systolic and diastolic functions of the heart, after the successful modeling of the myocardial fibrosis model can be seen, the ejection fraction is reduced from 63.18 +/-2.51% to 42.34 +/-2.40%, while the ejection fraction of the anti-myocardial fibrosis drugs lesses, the low-dose prevention group of ganoderma lucidum spore oil, the medium-dose prevention group of ganoderma lucidum spore oil and the high-dose prevention group of ganoderma lucidum spore oil return to normal, and the numerical values are respectively: 59.20 + -4.28%, 50.85 + -1.89%, 51.85 + -1.89% and 61.23 + -2.15%, which were significantly different from the model control group, as shown in Table 3.
(c) A decrease in ejection fraction indicates impaired cardiac function and a return to elevated ejection fraction indicates improved cardiac function. The heart function improving effects of the low, medium and high dose prevention groups of ganoderma lucidum spore oil are 50.85 + -1.89%, 51.85 + -1.89% and 61.23 + -2.15%, respectively, and are similar to the effect of the anti-myocardial fibrosis drug group, as shown in fig. 3.
The above results show that the effect of ganoderma lucidum spore oil extracted from ganoderma lucidum according to a certain proportion on preventing myocardial fibrosis.
Table 2 ultrasonic test results of each group of mice (n is 12)
Expression vs model group P <0.05
(5) Measurement of serum fibrosis indices laminin and hyaluronidase HA
After the experiment is finished, blood is collected after the mouse is anesthetized, the whole blood is centrifuged for 10 minutes at 800g/L, and the obtained serum is stored in a refrigerator at the temperature of 80 ℃ below zero until the serum is used. Changes in laminin LN and hyaluronidase HA that reflect changes in the extracellular matrix were detected using radioimmunoassay.
The results show (see table 3 and fig. 4):
comparing the model control group with the blank control group, the laminin LN and the hyaluronidase HA of the model control group are obviously increased.
② compared with the model control group, the low, middle and high ganoderma lucidum spore oil prevention group HAs the effect of reducing myocardial fibrosis, compared with the model control group, the laminin in the serum is respectively reduced by 26.9%, 25.2% and 31.91%, and the hyaluronidase HA in the serum is respectively reduced by 22.4%, 20.1% and 30.8%, the difference HAs statistical significance.
③ the ganoderma lucidum spore oil HAs similar results after preventing and obviously reducing the content of extracellular matrix in serum and 42 days of treatment of losartan which is a medicament for resisting myocardial fibrosis, and obviously reduces the components LN and HA of the serum extracellular matrix, thereby showing that the ganoderma lucidum spore oil HAs the curative effect of preventing myocardial fibrosis.
Table 3 serum index test results (n-12) for each group of mice
P <0.05, n-12 compared to model control
(6) Detection of superoxide dismutase (SOD), MDA and GSH in heart tissue
After the experiment is finished, the animal is euthanized, the chest is cut open, the heart is taken out, 20mL of 0.9% sodium chloride normal saline is used for flushing 3, after the blood water is cleaned, the left ventricle is taken out and used in a mortar, after liquid nitrogen grinding, phosphate buffer solution is added, and the SOD, MDA and GSH contents of the tissue are measured according to the reagent and the instruction. The unit of measurement was nml/mg protein.
Superoxide dismutase (SOD) is an important antioxidant enzyme in organisms, and is used for detecting secondary peroxidation injury after important organ injury and the drug treatment effect thereof; malondialdehyde MDA is an oxidative metabolite of lipids and unsaturated fatty acids, as lipid oxidation levels are monitored; glutathione GSH is a low-molecular free radical scavenger and is an important index for detecting the magnitude of the antioxidant capacity of a collective.
The results show (see table 4 and fig. 5):
compared with the model control group, the SOD level in the low, medium and high ganoderma lucidum spore oil prevention groups is obviously improved (P is less than 0.05), the SOD level is respectively improved by 58.3%, 60.0% and 79.6%, and the GSH also has the same trend; meanwhile, the MDA content in the low, medium and high concentration prevention groups of ganoderma lucidum spore oil is obviously reduced by 28.1 percent, 40.4 percent and 40.7 percent respectively.
The above results suggest that the intake of ganoderma lucidum spore oil can effectively improve the antioxidant capacity of the heart.
TABLE 4 SOD, MDA and GSH results for each group of mice (n. 12)
P <0.05, n-12 compared to model control
Application of Ganoderma lucidum spore oil in preparing functional food and medicine for preventing myocardial fibrosis caused by aortic valvular disease is provided. Furthermore, the pharmaceutical composition with the effect of preventing the myocardial fibrosis caused by aortic valvular disease can be prepared, and comprises auxiliary materials and functional food or pharmaceutical ingredients, wherein the functional food or pharmaceutical ingredients are the ganoderma lucidum spore oil. The dosage form of the pharmaceutical composition is emulsion or soft capsule. The adjuvants can be conventional adjuvants.
The present invention is illustrated by the following examples, which are not intended to limit the scope of the invention. Other insubstantial modifications and adaptations of the present invention can be made without departing from the scope of the present invention.
Claims (3)
1. Application of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil in preparing medicine for preventing myocardial fibrosis caused by aortic valvular disease;
the ganoderma lucidum spore oil is prepared by the following method:
(1) selecting 1000g of ganoderma lucidum spore powder, carrying out ultrasonic treatment, freezing the ganoderma lucidum spore powder subjected to ultrasonic treatment for multiple times by adopting liquid nitrogen, then rewarming, then adding neutral protease for enzymolysis, and carrying out enzyme inactivation, neutralization, filtration and drying treatment after enzymolysis to obtain pretreated ganoderma lucidum spore powder;
(2) performing supercritical extraction on the pretreated ganoderma lucidum spore powder by adopting carbon dioxide to obtain ganoderma lucidum spore oil;
freezing the ganoderma lucidum spore powder subjected to ultrasonic treatment for 3 times by adopting liquid nitrogen in the step (1), and then rewarming at 30 ℃;
in the step (1), the temperature is 50 ℃, the enzymolysis time is 60min, and the pH value is 7.4;
the neutralization in the step (1) adopts potassium hydroxide, the drying temperature is 50 ℃, and the drying time is 10 hours;
when supercritical extraction is carried out by adopting carbon dioxide in the step (2), the extraction pressure is 15Mpa, the temperature is 40 ℃, and the time is 2 hours; separating at 30 deg.C under 6Mpa for CO2The speed is 20L/h;
the mass percentage of the ganoderma lucidum spore oil in the step (2) is 27%, the ganoderma lucidum spore oil comprises ganoderma lucidum total triterpenes and fatty acids, the ganoderma lucidum total triterpenes account for 18.7% of the total mass of the ganoderma lucidum spore oil, the fatty acids account for 74% of the total mass of the ganoderma lucidum spore oil, and the fatty acids comprise oleic acid, palmitic acid and linoleic acid, wherein the oleic acid, the palmitic acid and the linoleic acid account for 61.5%, 15.6% and 13.3% of the total mass of the fatty acids.
2. Use according to claim 1, characterized in that: the pharmaceutical composition containing the ganoderma lucidum spore oil comprises the ganoderma lucidum spore oil and auxiliary materials.
3. Use according to claim 1, characterized in that: the dosage form of the pharmaceutical composition containing ganoderma lucidum spore oil is emulsion or soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811145935.3A CN109331049B (en) | 2018-09-29 | 2018-09-29 | New use of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811145935.3A CN109331049B (en) | 2018-09-29 | 2018-09-29 | New use of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109331049A CN109331049A (en) | 2019-02-15 |
| CN109331049B true CN109331049B (en) | 2021-08-20 |
Family
ID=65307339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811145935.3A Active CN109331049B (en) | 2018-09-29 | 2018-09-29 | New use of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109331049B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112680275B (en) * | 2021-03-22 | 2021-06-25 | 南昌之禾生物工程有限公司 | Supercritical extraction process of ganoderma lucidum spore oil with high extraction rate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105326868A (en) * | 2015-06-16 | 2016-02-17 | 吉林农业大学 | Treatment effect of ganoderma sinensis extract on bone fracture |
| CN108485794A (en) * | 2018-02-06 | 2018-09-04 | 青岛润达生物科技有限公司 | A kind of preparation method of ganoderma lucidum spore oil |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1944609A (en) * | 2006-10-20 | 2007-04-11 | 吴敏 | Compound glossy ganoderma spore oil and its preparing method |
| CN105193867B (en) * | 2014-05-29 | 2019-03-05 | 南京中科药业有限公司 | A kind of ganoderma lucidum spore oil and preparation method thereof rich in ergosterol |
-
2018
- 2018-09-29 CN CN201811145935.3A patent/CN109331049B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105326868A (en) * | 2015-06-16 | 2016-02-17 | 吉林农业大学 | Treatment effect of ganoderma sinensis extract on bone fracture |
| CN108485794A (en) * | 2018-02-06 | 2018-09-04 | 青岛润达生物科技有限公司 | A kind of preparation method of ganoderma lucidum spore oil |
Non-Patent Citations (4)
| Title |
|---|
| "The anti-cancer components of Ganoderma lucidum possesses cardiovascular protective effect by regulating circular RNA expression;Yi-Zhen Xie，等;《Oncoscience》;20160828;第3卷(第7-8期);第203页摘要 * |
| 灵芝多糖对糖尿病大鼠心肌纤维化的保护作用;郑丽;《中国医院药学杂志》;20111030;第31卷(第20期);第1706-1710页 * |
| 灵芝孢子食用方法与破壁技术研究进展;张守勤，等;《农业机械学报》;20040401;第35卷(第02期);第160-162页 * |
| 红景天及灵芝孢子粉对自发性高血压大鼠肥厚心肌脂联素信号通路的影响;张智国，等;《中国中西医结合杂志》;20090320;第29卷(第03期);第233-237页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109331049A (en) | 2019-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462948B (en) | A kind of non-alcoholic fatty liver disease model preparation method | |
| CN109331049B (en) | New use of Ganoderma lucidum spore oil and/or pharmaceutical composition containing Ganoderma lucidum spore oil | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN101548966A (en) | Application of salvianolic acid A in salvia miltiorrhiza | |
| WO2012079419A1 (en) | Pharmaceutical composition for treating macular degeneration | |
| CN111870639A (en) | Application of Tibetan medicine scindapsus aureus in preparing medicine for treating atherosclerosis | |
| CN105395771B (en) | A kind of new warm kidney production of sperm drink and preparation method thereof | |
| CN107157980B (en) | Application of oridonin in preparation of anti-myocardial remodeling drugs | |
| KR101498665B1 (en) | Pharmaceutical composition and functional food for prevention or treatment of diabetic complications or angioedema comprising natural extract | |
| CN102475736B (en) | Application of mongolian milkvetch root extract | |
| CN103417907B (en) | A kind of application of Chinese medicine composition in the medicine for suppressing angiogenesis is prepared | |
| CN106963803B (en) | Application of gynostemma pentaphylla total flavone in preparing medicine for preventing and treating cardiac hypertrophy | |
| CN102631358A (en) | Application of polydatin in preparing medicament for treating diabetic nephropathy | |
| CN105250248A (en) | Application of astaxanthin in preparation of drugs for prevention and treatment of glomerular fibrosis and edema | |
| Bazekin et al. | Morphofunctional Assessment of the Glycyrrhizinic Acid Effect on Myocardium of Rats under Adrenaline Loading. | |
| CN107095974A (en) | A kind of hypoglycemic composition | |
| CN111297937A (en) | Application of emblic leafflower fruit ethyl acetate extract in preventing and treating atherosclerosis | |
| CN102526195B (en) | Medicinal composition for treating coronary disease and preparation method thereof | |
| CN113768956A (en) | Effect of cell-free fat extract on macrophage polarization regulation and disease treatment | |
| CN114010658B (en) | TREM2 hi Application of macrophage in preparing medicine for treating cardiac dysfunction | |
| CN117224527A (en) | Application of quercetin in preparation of medicines for preventing and treating hypertension combined left ventricular hypertrophy | |
| CN117618416A (en) | Application of substances for synthesizing epoxidized polyunsaturated fatty acid and metabolic pathway in preparation of myocardial infarction drugs | |
| JP2018501264A (en) | Lymphatic drainage composition for obese subjects | |
| CN105267632A (en) | Traditional Chinese medicine composition composition treating diabetic macular edema | |
| CN104997814B (en) | Application of the cordyceps sinensis in preventing and treating chronic vascular dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |